India Ophthalmology PACS Market Size, Share, Growth, and Industry Analysis, By Software Type (Integrated PACS SoftwarePACS integrated with Ophthalmology Information Systems (OIS)EHR/EMR integrated PACSRIS-integrated PACS, Standalone PACS Software, Cloud-Based PACS Software, AI-Enabled PACS Software), By Deployment Mode (On-premisesIn-house InfrastructureCustom Deployment, Cloud-basedPublic CloudPrivate CloudHybrid Cloud, Web-basedThin Client PACSZero-footprint PACS) and Forecast, 2026-2034

India Ophthalmology PACS Market Trends

Cloud, AI and Remote Ophthalmic Imaging Reshape Clinical Workflows

India's eye-care digitization is moving toward connected image repositories, browser-accessible visualization, artificial intelligence and remote clinical workflows. A 2025 multicentric Indian diabetic-retinopathy study evaluated 5,029 participants and 10,058 retinal images; its AI system recorded 92% sensitivity, 88% specificity and 100% sensitivity for referable diabetic retinopathy. These performance levels illustrate why AI-assisted image analysis is increasingly relevant to high-volume screening and PACS-connected workflows.

Teleophthalmology is simultaneously extending imaging beyond tertiary hospitals. DigiDrishti combines mobile applications with a web-based teleophthalmology system, while India's centralized remote ophthalmology infrastructure supports digital patient records, referrals and specialty eye-care delivery through vision centers. In 2025, MadhuNETrAI was reported to deliver more than 95% detection accuracy after validation involving 3,000–4,000 images selected from a pool of 13,000. These shifts reinforce India Ophthalmology PACS Market demand for scalable archives, interoperability and remote image access.

India Ophthalmology PACS Market Drivers

Expanding Digital Eye Screening and Connected Diagnostic Infrastructure

The expanding volume of retinal imaging is strengthening requirements for centralized storage, rapid retrieval and interoperable clinical workflows. India's first AI-driven community diabetic-retinopathy screening initiative was launched in December 2025 through AFMS, AIIMS and the Ministry of Health & Family Welfare. Separately, multicentric AI research involving 10,058 retinal images reported diabetic-retinopathy prevalence of 13.7% overall and 38.2% among participants with elevated random blood glucose, alongside 92% sensitivity and 88% specificity. The resulting image volumes and referral requirements support India Ophthalmology PACS Market growth through automated routing, longitudinal comparison and centralized image management.

India Ophthalmology PACS Market Restraints

Integration Costs and Fragmented Ophthalmic Imaging Workflows

Deployment remains constrained by interoperability, infrastructure investment, cybersecurity requirements and heterogeneous imaging equipment. AI-enabled workflows require consistent image quality, device connectivity and standardized clinical processes; field research has identified paper-based workflows, domain shift and image-quality variability as barriers to scalable AI-assisted screening. With retinal AI systems commonly targeting sensitivity above 90%, workflow failures can undermine otherwise strong algorithmic performance. A 5,029-participant Indian validation study still required 10,058 images and specialist comparison, demonstrating the data and validation intensity associated with dependable deployment.

India Ophthalmology PACS Market Opportunities

AI-Assisted Screening Creates a Scalable Imaging Ecosystem

Large-scale diabetic-retinopathy screening presents a significant PACS opportunity because every screening episode can generate retinal images requiring storage, transfer, analysis and longitudinal access. Forus Health's AI diabetic-retinopathy solution received Indian regulatory approval as Class C Software as a Medical Device; reporting around the approval cited approximately 89.8 million Indian adults living with diabetes in 2024 and diabetic-retinopathy prevalence reaching up to 17%. AI models demonstrating 92% sensitivity, 88% specificity and 100% sensitivity for referable disease further strengthen the technical case for integrating diagnostic algorithms with image-management platforms.

Challenges in India Ophthalmology PACS Market

Data Standardization, Security and Last-Mile Connectivity

Scaling ophthalmic PACS across hospitals, clinics and remote screening sites requires consistent DICOM handling, HL7/EHR connectivity, cybersecurity controls and dependable network infrastructure. Mobile and AI-supported screening can generate thousands of images rapidly: one Indian study processed 10,058 retinal images from 5,029 participants, while MadhuNETrAI validation reportedly drew on a 13,000-image pool and achieved above 95% detection accuracy. Maintaining image quality, consent, secure transmission, clinical traceability and device interoperability across these volumes remains a central operational challenge.

India Ophthalmology PACS Market Segmentation

The market is segmented by software type, deployment mode, functionality/module, application, end user and business model. Integrated PACS Software accounts for approximately 30.0% of software revenue in 2026, while on-premises deployment represents approximately 45.0% of deployment revenue. Cloud and AI categories nevertheless record the strongest expansion rates.

By Software Type

Integrated PACS Software is the largest software category, increasing from USD 4.46 million in 2025 to USD 4.78 million in 2026 and USD 8.28 million by 2034, at a 7.12% CAGR. It includes OIS-integrated, EHR/EMR-integrated and RIS-integrated configurations.

AI-Enabled PACS Software is the fastest-growing category at 7.88% CAGR, advancing from USD 1.60 million in 2026 to USD 2.93 million by 2034. Other categories include standalone, cloud-based, web-based and mobile-compatible platforms; cloud-based software itself records a 7.62% CAGR.

By Deployment Mode

On-premises is the largest deployment model at USD 7.16 million in 2026 and is forecast to reach USD 12.67 million by 2034, registering a 7.39% CAGR. Its 2026 contribution is approximately 45.0%, supported by in-house infrastructure and customized deployments.

Cloud-based deployment is the fastest-growing model at 7.63% CAGR, rising from USD 4.96 million in 2026 to USD 8.94 million by 2034. Web-based deployment follows at 7.54% CAGR and reaches USD 6.81 million by 2034.

By Software Functionality / Module

Image archiving and storage remains a foundational functionality because PACS platforms consolidate high-resolution diagnostic images and longitudinal records. Modules additionally cover workflow management, 2D/3D visualization, DICOM integration, reporting, analytics, HL7/EHR interoperability, teleophthalmology, security and AI-assisted diagnostics.

AI-based analysis and remote viewing represent faster-developing functional layers as screening programs scale. Clinical AI evidence showing 92% sensitivity, 88% specificity and 100% referable-DR sensitivity reinforces demand for PACS architectures capable of connecting image acquisition, automated analysis and specialist review.

By Application

Clinical diagnosis represents the core application, covering retina disorders, glaucoma, cataract and corneal disease. High imaging intensity in diabetic retinopathy and retinal disease makes longitudinal image comparison particularly important; one multicentric study evaluated 10,058 retinal images across 5,029 participants.

Tele-ophthalmology is an expanding application, including remote consultation and AI-based diagnosis. MadhuNETrAI reportedly achieved above 95% detection accuracy, while India's digital eye-care infrastructure increasingly connects community screening with specialist referral.

By End User

Hospitals, particularly specialty eye hospitals, represent major PACS users because they combine high patient throughput with multiple imaging modalities and long-term follow-up requirements. Ophthalmology clinics, diagnostic imaging centers, ASCs and academic institutions constitute additional demand centers.

Remote and community settings are becoming increasingly relevant. The 2025 AFMS initiative introduced AI-driven diabetic-retinopathy screening, creating an operational model linking community image acquisition with specialist-level interpretation and referral.

By Business Model

Perpetual licensing remains relevant for institutions favoring controlled on-premises infrastructure, while subscription-based SaaS aligns with cloud deployment, remote access and lower upfront IT requirements. Pay-per-use and supported open-source approaches address lower-volume and cost-sensitive installations.

Subscription models benefit from recurring upgrades, cybersecurity maintenance and scalable storage. With cloud deployment advancing at 7.63% CAGR and cloud-based software at 7.62%, recurring software models are positioned to gain importance through 2034.

India Ophthalmology PACS Market Counties Outlook

Regional monetary shares are not supplied; consequently, North, South, West, East and Central India are not assigned fabricated percentages. Nationally, the market stands at USD 15.93 million in 2026 and reaches USD 28.42 million by 2034 at 7.52% CAGR. On-premises deployment contributes approximately 45.0% in 2026, cloud-based 31.1%, and web-based 23.9%.

South and West India benefit from major metropolitan healthcare and technology clusters, while North India gains from national referral institutions and government-backed screening initiatives. East and Central India offer expansion potential through remote-care models. Vendor infrastructure also supports geographic penetration: ZEISS reports 3 production facilities and about 40 sales and service offices across Tier I and Tier II Indian cities. State-level production and revenue splits are not available in the mandatory dataset.

Top players in India Ophthalmology PACS Market

• Carl Zeiss Meditec AG
• Heidelberg Engineering GmbH
• Topcon Corporation
• Agfa-Gevaert
• IBM/Merge Healthcare
• Koninklijke Philips N.V.
• GE HealthCare
• Siemens Healthineers
• FUJIFILM
• Canon Medical Systems
• Sectra AB
• Visage Imaging
• RamSoft
• INFINITT Healthcare
• EyePACS

The competitive set includes ophthalmology-specialist imaging vendors and broader enterprise imaging companies.

Top Two Companies

• Carl Zeiss Meditec AG

Exact India-specific revenue share is not publicly disclosed; assigning an unsupported percentage would conflict with the supplied-data requirement. ZEISS maintains a significant ophthalmic imaging position through integrated diagnostic and digital workflows. Its Indian organization reports 3 production facilities, an R&D center and approximately 40 sales and service offices spanning Tier I and Tier II cities, providing substantial commercial and service reach. Its competitive positioning centers on connecting ophthalmic diagnostic equipment, image management and clinical workflows.

• Heidelberg Engineering GmbH

Exact India-specific percentage share is likewise not disclosed in the provided dataset or cited company information. Heidelberg Engineering positions its portfolio around multimodal retinal imaging, anterior-segment diagnostics, surgical visualization and ophthalmic IT. The company states that eye-care professionals in more than 120 countries use its technologies, while Heidelberg Eye Explorer forms part of its healthcare-IT offering. This integrated imaging-plus-data strategy supports its position among specialized ophthalmology PACS competitors.

Recent Developments in India Ophthalmology PACS Market

• 2026:India's DigiDrishti digital eye-care system continued supporting mobile and web-based teleophthalmology, remote primary eye care and referral management.
• 2026:Forus Health received CDSCO approval for FH-POISE DRT, an AI-powered diabetic-retinopathy screening solution classified as Class C Software as a Medical Device.
• 2025:AFMS, AIIMS and the Ministry of Health & Family Welfare launched India's first AI-driven community diabetic-retinopathy screening program on December 16, 2025.
• 2025:MadhuNETrAI emerged as an AI-assisted retinal-screening platform with reported detection accuracy exceeding 95% following validation on 3,000–4,000 images from a 13,000-image pool.
• 2025:A multicentric Indian AI diabetic-retinopathy study involving 5,029 participants and 10,058 retinal images reported 92% sensitivity, 88% specificity and 100% sensitivity for referable disease.

Research Methodology

The assessment uses 2025 as the base year, 2026 as the current year, 2022–2024 as the historical period and 2026–2034 as the forecast horizon. Mandatory supplied numerical tables constitute the primary source for market values, segment contributions and CAGRs; percentage shares are calculated directly from those values where required. Secondary validation uses government resources, company disclosures, regulatory developments and clinical research. No unavailable state-level market shares, company shares, production volumes or segment forecasts were fabricated. Quantitative comparisons were cross-checked for consistency, while qualitative analysis evaluates digitization, cloud migration, interoperability, AI-assisted diagnostics, teleophthalmology and competitive positioning.